| Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. | |
| | |
MedLine Citation:
|
PMID: 12865867 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To determine the additional value of [(18)F]FDG-PET in combination with computed tomography (CT) over CT used alone, for evaluating ovarian cancer patients after primary treatment. METHODS: Twenty-five women (mean age: 53.6 years) had primary debulking surgery followed by chemotherapy for histologically proven ovarian carcinoma. At initial diagnosis, the tumor types were papillary serous adenocarcinoma (n=20), endometroid carcinoma (n=3), mixed mullerian tumor (n=1), and granulosa cell tumor (n=1). All patients underwent [(18)F]FDG-PET and contrast enhanced CT examinations, within 30 days of the completion of chemotherapic treatment. [(18)F]FDG-PET images were interpreted with the knowledge of CT findings (PET+CT); conversely, CT images were evaluated with no knowledge of the [(18)F]FDG-PET results. Within 7 day of imaging studies, 2(nd)-look laparoscopy (n=7) or laparotomy (n=18) was performed for histological confirmation. In all cases, imaging findings were then correlated with results of histopathologic examination. RESULTS: Of the 23 neoplastic viable lesions, all histologically confirmed, 16 could be detected by CT alone and 19 by PET+CT. An inflammatory lymph-node was misdiagnosed as viable tumor with both PET+CT and CT alone; an area of scar tissue in the presacral region was also misinterpreted as malignant tissue with CT alone. Overall lesion-based sensitivity, specificity and accuracy in assessing focal areas of residual tumor were as follows: 69.56%, 83.33%, 74.28% for CT, and 82.60%, 91.67%, 85.71% for PET+CT. The negative predictive value of PET+CT was markedly higher (73.33%), compared to that of CT alone (58.82%). CONCLUSION: PET used in combination with CT allows to accurately assess tumor response. A major advantage of PET+CT over CT alone is in excluding the presence of residual viable lesions after treatment. |
| | |
Authors:
|
M Picchio; S Sironi; C Messa; G Mangili; C Landoni; L Gianolli; B Zangheri; R Viganò; G Aletti; P De Marzi; F De Cobelli; A Del Maschio; A Ferrari; F Fazio |
Related Documents
:
|
1643607 - Imaging lung cancer by scintigraphy with indium 111-labeled f(ab')2 fragments of the an... 19091887 - The effectiveness of 18f-fdg pet/ct combined with stir mri for diagnosing nodal involve... 18805147 - Assessment of treatment response and recurrence in esophageal carcinoma based on tumor ... 19593687 - Early detection of recurrence after endoscopic treatment for early gastric cancer. 17092517 - Prediction of cognitive decline after stroke using proton magnetic resonance spectroscopy. 15104317 - Daily target localization for prostate patients based on 3d image correlation. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) Volume: 47 ISSN: 1125-0135 ISO Abbreviation: Q J Nucl Med Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-07-16 Completed Date: 2004-05-17 Revised Date: 2007-01-10 |
Medline Journal Info:
|
Nlm Unique ID: 9512274 Medline TA: Q J Nucl Med Country: Italy |
Other Details:
|
Languages: eng Pagination: 77-84 Citation Subset: IM |
Affiliation:
|
IBFM-CNR, University of Milano-Bicocca, University of Vita-Salute, Institute H. San Raffaele, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Female Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplasm Recurrence, Local / radiography*, radionuclide imaging* Ovarian Neoplasms / diagnosis*, radiography, radionuclide imaging, therapy* Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Subtraction Technique* Tomography, Emission-Computed / methods* Tomography, X-Ray Computed / methods* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Syringomyelia associated with hydrocephalus and Blake's pouch cyst: case report.
Next Document: Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.